ABUS: arbutusbio.com Cash Calculated per Single Share

Symbol and logo of brand Tekmira Pharmaceuticals (ABUS)

Arbutus Biopharma (ABUS) operates on investment capital while awaiting the commercialization of its hepatitis B drugs. The robotization of RNA therapy screening is accelerating the search for formulas, which is confirmed by the historical trend of cash position per share on the GURU.Markets chart, where the current value is 2.22. A robust scientific foundation and the support of strategic partners in the fight against viral liver diseases guarantee the stability of the business in the US.

Arbutus (ABUS): Cash Funds per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for Arbutus Biopharma Corporation (ABUS)

- price and consensus price forecast:
- cash and cash flow data:
Summary company analysis:Arbutus Biopharma
Flagship merchandise of arbutusbio.com

Investors must evaluate the fundamental stability of the asset through the amount of free capital per share, which allows for the determination of real liquidity and the business's margin of safety. Analyzing the cash-per-share structure reveals Arbutus Biopharma (ABUS) dependence on irregular partner payments and licensing fees, which is critical given the low predictability of cash flows in drug development.